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Abstract
Summary Addition of 10 mg prednisone daily to a
methotrexate-based tight control strategy does not lead to
bone loss in early rheumatoid arthritis (RA) patients receiving
preventive treatment for osteoporosis. A small increase in
lumbar bone mineral density (BMD) during the first year of
treatment was recorded, regardless of use of glucocorticoids.
Introduction This study aims to describe effects on
BMD of treatment according to EULAR guidelines with
a methotrexate-based tight control strategy including
10 mg prednisone daily versus the same strategy without
prednisone in early RA patients who received preventive
therapy for osteoporosis.
Methods Early RA patients were included in the CAMERA-II
trial: a randomized, placebo-controlled, double-blind 2-year
trial, in which effects of addition of 10 mg prednisone daily
to a methotrexate-based tight control strategy were studied. All
patients received calcium, vitamin D and bisphosphonates.
Disease activity was assessed every 4 weeks. Radiographs of
hands and feet and dual-energy X-ray absorptiometry of lum-
bar spine and left hip were performed at baseline and after 1
and 2 years of treatment.
Results BMD increased significantly over time in both treat-
ment groups at the lumbar spine with a mean of 2.6 %
during the first year (p<0.001), but not at the hip; at none
of the time points did BMD differ significantly between the
prednisone and placebo group. Higher age and lower weight
at baseline and higher disease activity scores during the trial,
but not glucocorticoid therapy, were associated with lower
BMD at both the lumbar spine and the hip in mixed-model
analyses.
Conclusion Addition of 10 mg prednisone daily to a
methotrexate-based tight control strategy does not lead to
bone loss in early RA patients on bisphosphonates. A small
increase in lumbar BMD during the first year of treatment
was found, regardless of use of glucocorticoids.
Keywords Bone mineral density . Glucocorticoids .
Osteoporosis . Rheumatoid arthritis
Introduction
Glucocorticoids (GCs) are frequently used in the treatment
of rheumatoid arthritis (RA) [1]. They are effective in
retarding the progression of erosive joint damage in early
RA and lead to a faster and better control of disease activity
[2–9]. However, the use of these drugs is restrained by the
occurrence (and fear) of side effects [10, 11].
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According to recent EULAR recommendations on the
management of RA, the first step after diagnosis is starting
a tight control treatment with methotrexate with or without
GCs [12]. Addition of GC therapy to a tight control strategy
has many positive effects, which have been shown recently
in the CAMERA-II (second Computer-Assisted Manage-
ment in Early Rheumatoid Arthritis) trial. In this study, the
effects of the addition of 10 mg prednisone daily to a tight
control methotrexate-based treatment were studied in
patients with early RA [13]. Co-treatment with prednisone
instead of placebo led to better control of disease activity
and to reduced erosive joint damage. The mean dose of
methotrexate and the need for biological treatment were
decreased. Analyzing the number of patients experiencing
at least once a specific adverse event during the study, there
were no significant differences, except for less patients in
the prednisone group experiencing nausea (p00.006),
ALAT>upper limit of normal (p00.006), and ASAT>upper
limit of normal (p00.016) compared to patients in the placebo
group. Although prophylactic medication for osteoporosis
was given, a drawback of the treatment with GCs could be
the risk of bone density loss and fractures.
In the first randomized, placebo-controlled study on GC-
induced osteoporosis, treatment with slow-acting intramus-
cular gold salts and 10 mg prednisone daily in the absence
of prophylactic medication for osteoporosis led to rapid
bone loss in patients with RA, which was partly reversible
after discontinuation of prednisone treatment [14]. Caution
should be taken in interpreting these data because measure-
ments were performed by dual-energy quantitative comput-
ed tomography, which has a relatively low precision.
Although the results from other individual studies thereafter
with low- to medium-dose GC therapy in RA are inconsis-
tent [3, 6, 15–17], a meta-analysis showed strong correla-
tions between the cumulative GC dose and a decline in bone
mineral density (BMD) and between the daily dose and risk
of fracture [18].
In RA, bone loss in GC-naive patients may develop; this
mainly occurs during the first months of disease [19, 20] and
especially in patients with active disease [21–23]. Systemic
inflammation, not only via interleukin-1 (IL-1) and tumor
necrosis factor (TNF) leads to bone loss, but also via
decreased weight-bearing physical activity [24], because of
pain and stiffness [25]. The impaired mobility also reduces
exposure to sunlight which is needed for sufficient amounts of
vitamin D, increasing the risk of developing osteoporosis [26,
27] and the risk of falls, leading to fractures. Furthermore, RA
patients are mostly women of whom the majority are
postmenopausal [25], thus comprising individuals already at
high risk of developing osteoporosis. In these circumstances,
the negative effects of GCs might be the trigger for definite
worsening of the BMD. Although it has been established that
preventive medication for osteoporosis (i.e., calcium, vitamin
D, bisphosphonates) is effective in inhibiting bone loss and
their use is recommended [28], it is also known that adherence
to bisphosphonate therapy is low, and this is associated with
an increased fracture risk [29]. This makes the fear for
development of osteoporosis with chronic prednisone
therapy of 10 mg daily in RA patients a realistic concern
despite the prescription of preventive therapy.
On the other hand, one could argue that effective therapy
could decrease the risk of osteoporosis induced by disease
activity. Both treatment strategies in the CAMERA-II trial
are treat-to-target strategies aiming at remission, and it
might be that the inclusion of prednisone is not as harmful
as expected based on earlier reports. The net effects of GCs
on bone in RA thus remain controversial: do favorable
effects on the inflammatory disease and thus on physical
activity outweigh the negative effects on bone (see Fig. 1)?
In this paper, we describe the effects on bone of adding
GC therapy to a tight control strategy in early RA. Primary
analyses are focused on BMD changes over time and differ-
ences between the prednisone and placebo group. Secondary
analyses have been performed to identify the influence of
disease characteristics and additional (according to protocol)
anti-TNF alpha treatment on BMD.
Methods
CAMERA-II trial
From 2003 until 2008, 236 early RA patients were included
in the CAMERA-II trial [13]. This was a randomized,
placebo-controlled, double-blind multi-center, tight control
strategy and treat to target (remission) trial, in which the
effects of the addition of 10 mg prednisone daily to a
methotrexate-based treatment strategy were studied. All
patients were adults who met the 1987 revised American





Fig. 1 BMD is influenced by GCs and active RA. Both GC therapy
and active rheumatoid arthritis (RA) are thought to influence bone
mineral density (BMD) in a negative way. However, GCs decrease
the disease activity of RA. Therefore, they may exert a positive effect
on BMD by lowering inflammation. Actually, the net effect is un-
known. BMD bone mineral density, GC glucocorticoid, RA rheumatoid
arthritis
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duration of less than 1 year. They had not been treated with
disease-modifying anti-rheumatic drugs including GCs be-
fore. Treatment was started with 10 mg methotrexate week-
ly. All patients received bisphosphonates (81 % started
alendronate; others received risedronate). According to
study protocol, calcium supplementation was 500 mg and
vitamin D was 400 IE—both usual doses at the time the
study was designed. Use of this supplementation was
recorded in more than 90 % of patients. Folic acid 0.5 mg
daily except for the day of methotrexate intake was also
prescribed. Use of nonsteroidal anti-inflammatory drugs
was allowed.
At baseline and every 4 weeks thereafter, the swollen
joint count (0–38 joints), tender joint count (0–38 joints),
erythrocyte sedimentation rate, and visual analog scale
(0–100 mm; 100 mm worst) for general well-being were
assessed. Treatment was intensified in case patients did not
improve sufficiently according to predefined criteria by
increasing the methotrexate dosage stepwise, switching to
subcutaneous therapy with methotrexate at maximal
(tolerated) oral methotrexate dose and as next step adding
adalimumab treatment, if needed [13]. If sustained remis-
sion (defined as a swollen joint count of 0 and at least two
out of the following three: tender joint count ≤3, visual
analog scale of well-being ≤20 mm, erythrocyte sedimenta-
tion rate ≤20 mm/h (1st), all during at least 3 months) was
achieved, methotrexate was reduced gradually by 2.5 mg/
week each month as long as remission was present. At base-
line and at year 1 and 2, radiographs of hands and feet were
taken and scored by two readers according to the Sharp–
vanderHeijde score (SHS) [30].
The study was approved by the medical research ethics
committees of all centers involved (clinical trial registration
number ISRCTN70365169) and had therefore been per-
formed in accordance with the ethical standards laid down in
the 1964 Declaration of Helsinki. All patients gave written
informed consent.
BMD measurements
At baseline and after 1 and 2 years of treatment, dual-energy
X-ray absorptiometry (DXA) was performed. BMD was
measured in five centers both at the lumbar spine and left
hip, in three centers assessing the total hip, and in two
centers assessing the femoral neck. Three centers used
Hologic machines (Hologic, Bedford, MA, USA), one cen-
ter used a Lunar machine (General Electric, Madison, WI,
USA), and one center used a Norland machine (Cooper
Surgical, Trumbull, CT, USA). BMD was expressed as
grams per square centimeter and T scores were given. A
patient is defined as having a normal BMD with T scores
of −1 or above at both lumbar spine and hip [31]. Patients
with T scores between −1 and −2.5 at lumbar spine and/or
hip are qualified as osteopenic [31]. A T score of −2.5 or
below at lumbar spine and/or hip indicated osteoporosis
[31].
Statistical analyses
The BMD values derived from the different machines and
different regions of the hip were calculated to standardized
BMD (sBMD) values with previously reported and validat-
ed formulas [32, 33]. Differences between the two groups in
means of continuous data were tested with independent-
samples t-tests or Mann–Whitney U-tests, where appropri-
ate, and differences in categorical data with chi-square tests.
Differences in sBMD values between the two groups
over time were tested using repeated-measures ANOVA.
Additionally, longitudinal regression analyses (mixed models)
were performed to assess the influence of patient character-
istics and disease severity on the course of sBMD. A random
intercept was used, and treatment group and time were inde-
pendent variables, and sBMD in the lumbar spine or left hip
(with separate analyses for these two variables) was the depen-
dent variable. Gender, age, weight, rheumatoid factor status,
baseline DAS28 (disease activity score based on 28 joints), and
average DAS28 during the trial period were used as covariates
in the models. Several interaction terms (i.e., treatment strate-
gy×gender, treatment strategy×age, treatment strategy×time,
age×time) were also tested in the models to investigate wheth-
er the effect of the treatment strategy on sBMD was constant
between subgroups and whether the effects of the treatment
strategy and age on BMD were constant over time. Using a
backward selection strategy, variables which did not contribute
to the model were removed from the model one by one. A
liberal p-value (p>0.20) was used for exclusion from the
model. In all models, treatment strategy and study center were
retained as covariates. Separate models were created including
SHS instead of DAS28 measurements or including adalimu-
mab treatment. Since mixed model analyses can account for
missing data (assumed to be missing at random), patients who
missed one or two BMD measurements were still included in
the longitudinal regression analyses.
The statistical software SPSS 18.0 and NCSS 2007 were
used for analyses of data. Unless stated otherwise, P values
below 0.05 were considered as statistically significant.
Results
Patient characteristics
The characteristics of the study population are shown in
Table 1 for the complete trial population and the group with
at least one BMDmeasurement during the trial. DXA scans at
0, 1, and 2 years were performed in respectively 73, 63, and
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61 % of the patients. The prednisone and placebo strategy
group in the current analyses did not differ significantly from
the original study groups for any of the baseline variables. The
two groups included in the current analyses only differed from
each other at baseline in the number of patients with rheuma-
toid factor and the mean DAS28.
BMD measurements
The mean sBMD levels for each treatment group at specific
time points are shown in Fig. 2. The sBMD increased signifi-
cantly over the first year of treatment in both treatment groups
in the lumbar spine (paired samples t-test with sBMD at 0 and
1 year, p<0.001 for the prednisone group and the placebo
group), with a mean increase in sBMD of 2.7 % in the predni-
sone group and 2.4 % in the placebo group. During the second
year of treatment, the BMD in the prednisone group showed a
small decrease to 2.4 % above baseline values (not significant),
while in the placebo group the BMD rose significantly to 3.4 %
above baseline values (p00.01). The sBMD in the left hip did
not change significantly during the 2 years of treatment.
Repeated-measures ANOVA also showed a significant
increase over 2 years’ time in the lumbar spine (F0
27.488, p<0.001). Significant differences between the
treatment strategies in sBMD or the trend over time
could not be demonstrated. In general, the trend over
time in sBMD was similar for men and women, al-
though the effect size was somewhat larger in women
(not significantly).
Influence of patient characteristics and disease severity
Longitudinal regression analyses (mixed models) were per-
formed to assess the influence of patient characteristics and
disease severity on the course of sBMD levels (see Tables 2 and
3). Higher age and lower weight at baseline were associated
with lower sBMD in the lumbar spine as well as in the hip. The
sBMD values at the hip were significantly higher in male
patients. The treatment strategy was not significantly related
to sBMD levels. Treatment with prednisone at a higher age
even resulted in a positive influence on the sBMD of the hip
(see age×treatment with prednisone term in Table 3).
Table 1 Characteristics of the patient groups in the CAMERA-II study and of the subgroups included in the BMD analyses











Female gender (n (%)) 70 (60) 72 (61) 0.849 50 (59) 61 (65) 0.403
Age (years, mean±SD) 54±14 53±13 0.493 55±13 52±13 0.177
RF positive (n (%)) 64 (55) 73 (61) 0.101 41 (58) 59 (75) 0.028
DAS28 (mean±SD) 5.8±1.3 5.5±1.1 0.045 5.7±1.2 5.3±1.1 0.025
Radiographic damage
present (n (%))
34 (29) 24 (20) 0.127 26 (31) 19 (22) 0.149
Erosion score (SHS, median, IQR) 0 (0–0) 0 (0–0) 0.337 0 (0–0) 0 (0–0) 0.223
sBMD lumbar spine (g/cm2, mean±SD) 1.13±0.17 1.11±0.17 0.544
sBMD left hip (g/cm2, mean±SD) 0.94±0.13 0.91±0.16 0.252
Normal BMD (n (%)) 52 (61) 55 (58) 0.180
Osteopenia (n (%)) 30 (35) 29 (31)
Osteoporosis (n (%)) 3 (4) 10 (11)
Study measurements
Mean DAS28 during trial (mean±SD) 2.6±1.0 3.2±1.1 <0.001 2.7±1.0 3.2±1.1 0.001
Radiographic damage
present at end (n (%))
35 (30) 44 (41) 0.310 27 (35) 35 (41) 0.499
Erosion score at end (SHS, median, IQR) 0 (0–0) 0 (0–2) 0.024 0 (0–0) 0 (0–2) 0.133
Hospitalization for symptomatic vertebral
fracture during trial (n (%))
1 (1) 0 (0) 0.312 1 (1) 0 (0) 0.292
Peripheral fracture during trial (n (%)) 1 (1) 0 (0) 0.312 1 (1) 0 (0) 0.292
Data concerning the patient groups of the original CAMERA-II study have been published elsewhere [13]
BMD bone mineral density, MTX methotrexate, RF rheumatoid factor, VAS visual analog scale, TJC tender joint count based on 36 joints, SJC
swollen joint count based on 36 joints, ESR erythrocyte sedimentation rate, CRP c-reactive protein, DAS28 disease activity score based on 28 joints,
n number, SD standard deviation, IQR interquartile range, SHS Sharp-Van der Heijde score, sBMD standardized bone mineral density
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Furthermore, disease severity was of influence, reflected by
the negative influence on sBMD of higher DAS28 (included
in the model as area under the curve of all DAS28 measure-
ments during the complete trial period) for the lumbar spine
and hip. A rheumatoid factor positive status did negatively
influence the sBMD at the lumbar spine, but not at the hip. If
the model for lumbar sBMD was created without the variable
“rheumatoid factor,” the model included 170 instead of 145
patients (72 % instead of 61% of the original trial population).
In that case, age and weight were still significantly associated
with lumbar sBMDvalues, but the influence of DAS28 during
the trial was just not significant anymore.
If the mixed models were created with baseline SHS and
progression of SHS during the trial instead of DAS28measure-
ments, a significant influence of progression of SHSwas found
(beta −0.007, 95%CI of beta −0.014 to −0.001, p00.03) at the
lumbar spine, but not at the hip.
Anti-TNF alpha treatment
During the trial, in 58 patients, adalimumab was added to the
strategy during the trial as protocolized strategy step because
of insufficient response to treatment with methotrexate and
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Fig. 2 sBMD in lumbar spine
and left hip over time. This
figure shows the sBMD during
the trial for the prednisone
(solid lines) and placebo
(dashed lines) group. BMD
values measured in lumbar
spine and left hip (total hip or
femoral neck) were recalculated
to sBMD values with
previously reported and
validated formulas [32, 33].
The figures include all sBMD
values of patients who had
BMD measurements at all time
points. Means and SD are
depicted. BMD bone mineral
density, sBMD standardized
bone mineral density
Table 2 Variables associated with lumbar sBMD over time
Beta 95 % CI p-value
Intercept 1.187 1.062 to 1.312 <0.001
Treatment with
prednisone
0.002 −0.034 to 0.037 0.93
Study center <0.001
Male gender −0.033 −0.072 to 0.007 0.11
Age −0.004 −0.005 to −0.003 <0.001
Weight 0.004 0.002 to 0.005 <0.001
Rheumatoid factor
positivity
−0.064 −0.101 to −0.026 <0.001
AUC DAS28 −0.019 −0.036 to −0.002 0.03
This mixed model includes 145 patients (61 % of the trial population)
with 374 sBMD measurements. Fixed effects, except for the beta’s of
the different study centers, are described in the table. Study center,
higher age, lower weight, rheumatoid factor positivity, and higher
DAS28 during the trial were significantly related with lower sBMD
values at the lumbar spine
sBMD standardized bone mineral density, CI confidence interval,DAS28
disease activity score based on 28 joints, AUC area under the curve
Table 3 Variables associated with left hip sBMD over time
Beta 95 % CI p-value
Intercept 0.905 0.792 to 1.017 <0.001
Treatment with
prednisone
−0.087 −0.190 to 0.016 0.10
Study center 0.01
Male gender 0.030 0.000 to 0.060 0.049
Age −0.004 −0.005 to −0.003 <0.001
Weight 0.003 0.002 to 0.004 <0.001
Baseline DAS28 0.013 0.000 to 0.025 0.05
AUC DAS28 −0.021 −0.035 to −0.007 <0.01
Age×treatment
with prednisone
0.002 0.000 to 0.004 0.04
This mixed model includes 167 patients (71 % of the trial population)
with 429 sBMD measurements. Fixed effects, except for the beta’s of
the different study centers, are described in the table. Study center,
female gender, higher age, lower weight, higher DAS28 during the
trial, and treatment with placebo at lower age were significantly related
with lower sBMD values at the left hip
sBMD standardized bone mineral density, CI confidence interval,DAS28
disease activity score based on 28 joints, AUC area under the curve
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prednisone or placebo. DXA scans at 0, 1, and 2 years were
performed in respectively 76, 84 and 71 % of these patients.
Of the patients who needed adalimumab, only 16 (28 %) had
been treated with prednisone. Patients who needed adalimu-
mab co-therapy had a significantly lower baseline sBMD at
the hip (mean 0.89±0.14 SD versus mean 0.94±0.15 SD,
p00.04) but not at the lumbar spine.
When we included the number of adalimumab injections
into the models, we found a positive impact of the number
of adalimumab injections on sBMD in the lumbar spine
(beta 0.003, 95 % CI of beta 0.000 to 0.006, p00.03), while
the influences of other variables stayed unchanged. At the
hip, the number of adalimumab injections was associated with
a decrease in sBMD (beta −0.003, 95 % CI of beta −0.004
to −0.001, p<0.01), while the influence of gender was not
significant anymore.
Discussion
In this paper, we describe that addition from start of therapy
of 10 mg prednisone daily to a methotrexate-based tight
control strategy does not lead to bone loss in early RA
patients treated with osteoporosis-preventive drugs. In fact,
there is an increase in BMD during the first year of treat-
ment regardless of the use of GCs.
Our findings of a minimal impact of GCs on bone and the
absence of significant differences between GC and placebo
group are in line with results of several earlier studies on
BMD in early RA [3, 6, 16, 17, 34]. There were small
increases in lumbar sBMD in both the GC and placebo
groups, possibly reflecting the effective dampening of the
inflammatory process in early RA, especially of pro-
inflammatory cytokines such as IL-1 and TNF. These have
direct effects on osteoclast formation and stimulate osteo-
blasts and T lymphocytes to produce receptor activator of
nuclear factor kappa B (RANK) ligand, leading to differen-
tiation and activation of osteoclasts [35–37].
To this increase in lumbar sBMD, the bone protective
medication prescribed in all our patients probably will also
have contributed. The changes in BMD in our study are
comparable to changes encountered in other studies on the
effectiveness of alendronate in GC-induced osteoporosis in
patients with RA and other inflammatory rheumatic diseases
who also received calcium tablets [38, 39]. Again, effects
were strongest on BMD of the lumbar spine [38]. In recent
guidelines, the use of bisphosphonates is recommended with
chronic prednisone use in dosages above 7.5 mg daily in
postmenopausal women and in men with age above 70 years
[40, 41]. In premenopausal women and men with age below
70 years, it is advised that additional BMDmeasurements be
performed to assess the need for bisphosphonates [40, 41].
This implicates that in our study some patients might have
not needed the osteoporosis preventive medication. Never-
theless, with ongoing inflammation and decrease in physical
activity, patients with RA are at a higher risk for developing
osteoporosis, and early intervention including bisphospho-
nates can be advocated.
This study revealed an influence of inflammation on BMD.
In the mixed model analyses, the DAS28 measurements dur-
ing the trial had a negative impact on BMD of both lumbar
spine and hip. This indicates that in active early RA the
benefits of GC therapy on the dampening of inflammation
outweigh the risk of developing osteoporosis if preventive
measures for osteoporosis have been taken. It is unclear
whether the positive effects on BMD also lead to a reduction
of the fracture risk since an increased risk of fracture has been
observed with the same BMD level in GC users compared to
non-GC users [42]. This suggests that bone structure
negatively influenced by GCs might also play a role.
A subgroup of patients with active disease who responded
insufficiently to treatment with methotrexate and prednisone
or placebo started anti-TNF alpha treatment with adalimumab
added to medication. The number of subcutaneous adalimu-
mab injections was positively associated with lumbar sBMD
and negatively with hip sBMD in our study. Because this
study had not been designed to assess the effects of adalimu-
mab and the number of patients starting adalimumab was
relatively small, no conclusions can be drawn on the effects
of anti-TNF medication on BMD.
The results of this study indicate that the use of 10 mg
prednisone in early RA following recent recommendations
should not be restricted by fears of GC-induced osteoporosis
if effective preventive measures are taken. Interestingly, the
increase in sBMD is mainly achieved during the first year of
treatment, while in the second year of treatment this increase
diminishes. This is in line with earlier studies on effects of
bisphosphonates on GC-induced osteoporosis [38, 39].
Based on this study, it is impossible to predict the effects
on sBMD if GCs are used for more than 2 years and to
speculate about a safe duration of GC treatment. The stag-
nation of BMD increase during the second year of treatment
might indicate that GCs are not harmful during the first
period of active disease but that GC treatment can still have
harmful effects during treatment of longer duration. In that
case, it can be advocated to recommend tapering and stop-
ping GC therapy as soon as possible after 2 years of treat-
ment, also because joint sparing properties have not been
proven for treatment duration of more than 2 years. Another
reason for the stagnation of BMD increase could be decreas-
ing rates of adherence to bisphosphonates. The adherence
has not been assessed in this trial, but a recent meta-analysis
showed a suboptimal adherence with a pooled mean medi-
cation possession ratio of 67 % [43]. It is possible that
suboptimal bisphosphonate intake in this trial has limited
positive effects of bisphosphonates.
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Our study has limitations. First, we had to recalculate
sBMD values because of the different DXA machines used
at the different hospitals and the different sites of the left hip
measured. Fortunately, frequently used and validated formu-
las for calculating “standardized” BMD values were avail-
able and could be applied in this study [32, 33]. Moreover,
in the mixed models, study center was included as a cova-
riate, providing an additional correction for the different
DXA machines and the (clinical) measurements in different
study centers. Second, not all patients underwent DXA
measurements, but more than three quarters had at least
one measurement and could be included in the mixed model
analyses, assuming that missing data are missing at random.
The placebo group also received preventive therapy for oste-
oporosis, and due to this design, direct comparison with GC-
naive RA patients not using this prophylactic medication is
not possible. Possibly, GC-naive patients without osteoporosis
preventive treatment would lose instead of increase bone in
BMD. In that case, the difference in BMD between patients on
GC treatment combined with preventive therapy for osteopo-
rosis on one hand, and GC-naive patients on the other hand,
would be larger than that found in this study.
In conclusion, addition of 10 mg prednisone daily from
start of therapy to a methotrexate-based tight control strate-
gy does not lead to bone loss in early RA patients receiving
preventive treatment for osteoporosis. In fact, a small in-
crease in BMD of the lumbar spine during the first year of
treatment was recorded, regardless of the use of GCs.
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